Technology
Health
Biotechnology
Cue Biopharma
$7.349876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$7.34
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.61 (-7.67%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell Cue Biopharma and other stocks, options, ETFs, and crypto commission-free!
About
Cue Biopharma, Inc. Common Stock, also called Cue Biopharma, is a biopharmaceutical company, which engages in the development of a novel and proprietary class of biologic drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Read More Its pipeline includes Immuno-oncology, CUE-100 framework, CUE-200 framework, and autoimmune disease. The company was founded on December 31, 2014 and is headquartered in Cambridge, MA.
Employees
46
Headquarters
Cambridge, Massachusetts
Founded
2014
Market Cap
164.54M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
95.28K
High Today
$8.00
Low Today
$6.75
Open Price
$7.99
Volume
69.10K
52 Week High
$16.24
52 Week Low
$4.16
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
2018 IPO
US
North America
News
Simply Wall StMar 13
Do Insiders Own Shares In Cue Biopharma, Inc. (NASDAQ:CUE)?
A look at the shareholders of Cue Biopharma, Inc. (NASDAQ:CUE) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes ‘a business with enduring competitive advantages that is run by able and owner-oriented people’. So it’s nice to see some insider ownership, because it may suggest that management is owner-oriented. Cue Biopharma is a smaller...
Price Paid on Robinhood
21% Lower
Right Now
52 Week Low
$4.16
Average Price Paid
$9.32
52 Week High
$16.24